Clinical Perspectives on Autoimmune Processes in Schizophrenia

Psychiatric Clinics of North America

Volumn 32, Issue 4, 2009, Pages 795-808

  Yum, Sun Young ^a   Yum, Sun Kyoung ^b   Kim, Tak ^b   Hwang, Michael Y ^a,c,d  

^a Geisinger Health Geisinger Commonwealth School of Medicine   (United States)

^b College of Medicine   (South Korea)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d Franklin Delano Roosevelt Hospital   (United States)

Author keywords

Autoimmune; Glia; Immune system; Schizophrenia

Indexed keywords

AUTOANTIBODY; CYTOKINE; INTERLEUKIN 1BETA; SEMAPHORIN;

AUTOIMMUNE DISEASE; BACTERIAL INFECTION; BEHCET DISEASE; CELIAC DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ENDOGENOUS RETROVIRUS; GLUTEN FREE DIET; HUMAN; INFLUENZA; LEUKOCYTE; MACROGLIA; MAJOR HISTOCOMPATIBILITY COMPLEX; MICROGLIA; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; RISK FACTOR; SARCOIDOSIS; SCHIZOPHRENIA; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS ENCEPHALITIS;

AUTOIMMUNE DISEASES; BACTERIAL INFECTIONS; BRAIN; HUMANS; IMMUNE SYSTEM; SCHIZOPHRENIA; VIRUS DISEASES;

EID: 70450286235     PISSN: 0193953X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psc.2009.09.003     Document Type: Review

References (105)

1. Swedo S.E., Leonard H.L., Schapiro M.B., et al. Sydenham's chorea: physical and psychological symptoms of St Vitus dance. Pediatrics 91 4 (1993) 706-713
2. Rothermundt M., Arolt V., Leadbeater J., et al. Cytokine production in unmedicated and treated schizophrenic patients. Neuroreport 11 15 (2000) 3385-3388
3. Ganguli R., Rabin B.S., Kelly R.H., et al. Clinical and laboratory evidence of autoimmunity in acute schizophrenia. Ann NY Acad Sci 496 (1987) 676-685
4. Wright P., Sham P.C., Gilvarry C.M., et al. Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophr Res 20 3 (1996) 261-267
5. Finney G.O. Juvenile onset diabetes and schizophrenia?. Lancet 2 8673 (1989) 1214-1215
6. Eaton W.W., Hayward C., and Ram R. Schizophrenia and rheumatoid arthritis: a review. [review]. Schizophr Res 6 3 (1992) 181-192
7. Eaton W.W., Byrne M., Ewald H., et al. Association of schizophrenia and autoimmune diseases: linkage of Danish national registers. Am J Psychiatry 163 3 (2006) 521-528
8. Rose N.R., and Bona C. Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol Today 14 9 (1993) 426-430
9. Brey R.L., Holliday S.L., Saklad A.R., et al. Neuropsychiatric syndromes in lupus: prevalence using standardized definitions. Neurology 58 8 (2002) 1214-1220
10. West S.G. Neuropsychiatric lupus. Rheum Dis Clin North Am 20 1 (1994) 129-158
11. Hanly J.G. Neuropsychiatric lupus. Rheum Dis Clin North Am 31 2 (2005) 273-298
12. Hirohata S., Iwamoto S., Miyamoto T., et al. A patient with systemic lupus erythematosus presenting both central nervous system lupus and steroid induced psychosis. J Rheumatol 15 4 (1988) 706-710
13. Conti F., Alessandri C., Bompane D., et al. Autoantibody profile in systemic lupus erythematosus with psychiatric manifestations: a role for anti-endothelial-cell antibodies. Arthritis Res Ther 6 4 (2004) R366-R372
14. Karassa F.B., Ioannidis J.P., Touloumi G., et al. Risk factors for central nervous system involvement in systemic lupus erythematosus. QJM 93 3 (2000) 169-174
15. Toubi E., Khamashta M.A., Panarra A., et al. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 99 4 (1995) 397-401
16. Isshi K., and Hirohata S. Association of anti-ribosomal P protein antibodies with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 39 9 (1996) 1483-1490 [Erratum in: Arthritis Rheum 1997;40(5):977]
17. Zandman-Goddard G., Chapman J., and Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum 36 5 (2007) 297-315
18. Press J., Palayew K., Laxer R.M., et al. Antiribosomal P antibodies in pediatric patients with systemic lupus erythematosus and psychosis. Arthritis Rheum 39 4 (1996) 671-676
19. Bonfa E., Golombek S.J., Kaufman L.D., et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 317 5 (1987) 265-271
20. Gerli R., Caponi L., Tincani A., et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus. prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 41 12 (2002) 1357-1366
21. Isshi K., and Hirohata S. Differential roles of the anti-ribosomal P antibody and antineuronal antibody in the pathogenesis of central nervous system involvement in systemic lupus erythematosus. Arthritis Rheum 41 10 (1998) 1819-1827
22. Nojima Y., Minota S., Yamada A., et al. Correlation of antibodies to ribosomal P protein with psychosis in patients with systemic lupus erythematosus. Ann Rheum Dis 51 9 (1992) 1053-1055
23. Mahler M., Kessenbrock K., Szmyrka M., et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 13 1 (2006) 77-83
24. Schneebaum A.B., Singleton J.D., West S.G., et al. Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. Am J Med 90 1 (1991) 54-62
25. Yoshio T., Masuyama J., Ikeda M., et al. Quantification of antiribosomal P0 protein antibodies by ELISA with recombinant P0 fusion protein and their association with central nervous system disease in systemic lupus erythematosus. J Rheumatol 22 9 (1995) 1681-1687
26. Schwartz M., Kormilachev M., Kushnir M., et al. Lupus anticoagulant and anticardiolipin antibodies in serum of patients treated with risperidone. J Clin Psychiatry 70 5 (2009) 769-771
27. Iyer H.V., Moudgil H., Newman P., et al. Chlorpromazine-associated antiphospholipid antibody syndrome. Ann Pharmacother 41 3 (2007) 528
28. Schwartz M., Rochas M., Toubi E., et al. The presence of lupus anticoagulant and anticardiolipin antibodies in patients undergoing long-term neuroleptic treatment. J Psychiatry Neurosci 24 4 (1999) 351-352
29. Ducloux D., Florea A., Fournier V., et al. Inferior vena cava thrombosis in a patient with chlorpromazin-induced anticardiolipin antibodies. Nephrol Dial Transplant 14 5 (1999) 1335-1336
30. Kanjolia A., Valigorsky J.M., and Joson-Pasion M.L. Clozaril-induced lupus anticoagulant. Am J Hematol 54 4 (1997) 345-346
31. Matsukawa Y., Satoh M., Itoh T., et al. Plasmapheresis for a schizophrenic patient with drug-induced lupus anti-coagulant. J Int Med Res 24 1 (1996) 147-150
32. Shen H., Li R., Xiao H., et al. Higher serum clozapine level is associated with increased antiphospholipid antibodies in schizophrenia patients. J Psychiatr Res 43 6 (2009) 615-619
33. Gaynor B., Putterman C., Valadon P., et al. Peptide inhibition of glomerular deposition of an anti-DNA antibody. Proc Natl Acad Sci U S A 94 5 (1997) 1955-1960
34. Katz J.B., Limpanasithikul W., and Diamond B. Mutational analysis of an autoantibody: differential binding and pathogenicity. J Exp Med 180 3 (1994) 925-932
35. Kowal C., Degiorgio L.A., Lee J.Y., et al. Human lupus autoantibodies against NMDA receptors mediate cognitive impairment. Proc Natl Acad Sci U S A 103 52 (2006) 19854-19859
36. Bona J.R., Fackler S.M., Fendley M.J., et al. Neurosarcoidosis as a cause of refractory psychosis: a complicated case report. Am J Psychiatry 155 8 (1998) 1106-1108
37. Koptagel-Ilal G., Tunçer O., Enbiyaoǧlu G., et al. A psychosomatic investigation of Behçet's disease. Psychother Psychosom 40 1-4 (1983) 263-271
38. Siva A., Kantarci O.H., Saip S., et al. Behçet's disease: diagnostic and prognostic aspects of neurological involvement. J Neurol 248 2 (2001) 95-103
39. Akman-Demir G., Serdaroglu P., and Tasçi B. Clinical patterns of neurological involvement in Behçet's disease: evaluation of 200 patients. The Neuro-Behçet Study Group. Brain 122 Pt 11 (1999) 2171-2182
40. Singh M.M., and Kay S.R. Wheat gluten as a pathogenic factor in schizophrenia. Science 191 4225 (1976) 401-402
41. Cascella N.G., Kryszak D., Bhatti B., et al. Prevalence of celiac disease and gluten sensitivity in the United States clinical antipsychotic trials of intervention effectiveness study population. Schizophr Bull (2009) [Epub ahead of print]
42. Dohan F.C. Cereals and schizophrenia data and hypothesis. Acta Psychiatr Scand 42 2 (1966) 125-152
43. Dohan F.C., Harper E.H., Clark M.H., et al. Is schizophrenia rare if grain is rare?. Biol Psychiatry 19 3 (1984) 385-399
44. Crow T.J. A re-evaluation of the viral hypothesis: is psychosis the result of retroviral integration at a site close to the cerebral dominance gene?. Br J Psychiatry 145 (1984) 243-253
45. Cooper S.J. Schizophrenia after prenatal exposure to 1957 A2 influenza epidemic. Br J Psychiatry 161 (1992) 394-396
46. Brown A.S., Schaefer C.A., Wyatt R.J., et al. Maternal exposure to respiratory infections and adult schizophrenia spectrum disorders: a prospective birth cohort study. Schizophr Bull 26 2 (2000) 287-295
47. Laing P., Knight J.G., Hill J.M., et al. Influenza viruses induce autoantibodies to a brain-specific 37-kDa protein in rabbit. Proc Natl Acad Sci U S A 86 6 (1989) 1998-2002
48. Fatemi S.H., Earle J., Kanodia R., et al. Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. Cell Mol Neurobiol 22 1 (2002) 25-33
49. Dickerson F.B., Boronow J.J., Stallings C., et al. Infection with herpes simplex virus type 1 is associated with cognitive deficits in bipolar disorder. Biol Psychiatry 55 6 (2004) 588-593
50. Dickerson F., Kirkpatrick B., Boronow J., et al. Deficit schizophrenia: association with serum antibodies to cytomegalovirus. Schizophr Bull 32 2 (2006) 396-400
51. Delisi L.E., Smith S.B., Hamovit J.R., et al. Herpes simplex virus, cytomegalovirus and Epstein-Barr virus antibody titres in sera from schizophrenic patients. Psychol Med 16 4 (1986) 757-763
52. Waltrip II R.W., Buchanan R.W., Summerfelt A., et al. Borna disease virus and schizophrenia. Psychiatry Res 56 1 (1995) 33-44
53. De Ronchi D., Bellini F., Cremante G., et al. Psychopathology of first-episode psychosis in HIV-positive persons in comparison to first-episode schizophrenia: a neglected issue. AIDS Care 18 8 (2006) 872-878
54. Dou H., Birusingh K., Faraci J., et al. Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. J Neurosci 23 27 (2003) 9162-9170
55. Dou H., Ellison B., Bradley J., et al. Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 25 37 (2005) 8375-8385
56. Jones-Brando L.V., Buthod J.L., Holland L.E., et al. Metabolites of the antipsychotic agent clozapine inhibit the replication of human immunodeficiency virus type 1. Schizophr Res 25 1 (1997) 63-70
57. Huang W.J., Liu Z.C., Wei W., et al. Human endogenous retroviral pol RNA and protein detected and identified in the blood of individuals with schizophrenia. Schizophr Res 83 2-3 (2006) 193-199
58. Yao Y., Schröder J., Nellåker C., et al. Elevated levels of human endogenous retrovirus-W transcripts in blood cells from patients with first episode schizophrenia. Genes Brain Behav 7 1 (2008) 103-112
59. Karlsson H., Bachmann S., Schröder J., et al. Retroviral RNA identified in the cerebrospinal fluids and brains of individuals with schizophrenia. Proc Natl Acad Sci U S A 98 8 (2001) 4634-4639
60. Dickerson F., Rubalcaba E., Viscidi R., et al. Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia. Schizophr Res 104 1-3 (2008) 121-126
61. Spencer M.D., Knight R.S., and Will R.G. First hundred cases of variant Creutzfeldt-Jakob disease: retrospective case note review of early psychiatric and neurological features. [review]. BMJ 324 7352 (2002) 1479-1482
62. Wall C.A., Rummans T.A., Aksamit A.J., et al. Psychiatric manifestations of Creutzfeldt-Jakob disease: a 25-year analysis. J Neuropsychiatry Clin Neurosci 17 4 (2005) 489-495
63. Vaughn Jr. W.T., Sullivan J.C., and Elmadjian F. Immunity and schizophrenia; a survey of the ability of schizophrenic patients to develop an active immunity following the injection of pertussis vaccine. Psychosom Med 11 6 (1949) 327-333
64. Wilcox J.A., and Nasrallah H. Sydenham's chorea and psychopathology. Neuropsychobiology 19 1 (1988) 6-8
65. Heath R.G., Krupp I.M., Byers L.W., et al. Schizophrenia as an immunologic disorder. 3. Effects of antimonkey and antihuman brain antibody on brain function. Arch Gen Psychiatry 16 1 (1967) 24-33
66. Heath R.G., Krupp I.M., Byers L.W., et al. Schizophrenia as an immunologic disorder. II. Effects of serum protein fractions on brain function. Arch Gen Psychiatry 16 1 (1967) 10-23
67. Jones A.L., Mowry B.J., Pender M.P., et al. Immune dysregulation and self-reactivity in schizophrenia: do some cases of schizophrenia have an autoimmune basis?. Immunol Cell Biol 83 1 (2005) 9-17
68. Rock R.B., Gekker G., Hu S., et al. Role of microglia in central nervous system infections. Clin Microbiol Rev 17 4 (2004) 942-964
69. Bayer T.A., Buslei R., Havas L., et al. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 271 2 (1999) 126-128
70. Radewicz K., Garey L.J., Gentleman S.M., et al. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 59 2 (2000) 137-150
71. van Berckel B.N., Bossong M.G., Boellaard R., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 64 9 (2008) 820-822
72. Steiner J., Bielau H., Brisch R., et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 42 2 (2008) 151-157
73. Landreth G.E., Sundararajan S., and Heneka M.T. Peroxisome proliferator-activated receptor gamma agonists: potential therapeutic agents for neuroinflammation. In: Wood P.L. (Ed). Neuroinflammation mechanisms and management. 2nd edition (2003), Humana Press, Totowa (NJ) Chapter 7. p. 152
74. Zheng L.T., Hwang J., Ock J., et al. The antipsychotic spiperone attenuates inflammatory response in cultured microglia via the reduction of proinflammatory cytokine expression and nitric oxide production. J Neurochem 107 5 (2008) 1225-1235
75. Kato T., Mizoguchi Y., Monji A., et al. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro. J Neurochem 106 2 (2008) 815-825
76. Bian Q., Kato T., Monji A., et al. The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 32 1 (2008) 42-48
77. Kato T., Monji A., Hashioka S., et al. Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro. Schizophr Res 92 1-3 (2007) 108-115
78. Drew P.D., and Chavis J.A. Female sex steroids: effects upon microglial cell activation. J Neuroimmunol 111 1-2 (2000) 77-85
79. Dalton K. Menstruation and acute psychiatric illnesses. Br Med J 1 5115 (1959) 148-149
80. Endo M., Daiguji M., Asano Y., et al. Periodic psychosis recurring in association with menstrual cycle. J Clin Psychiatry 39 5 (1978) 456-466
81. Riecher-Rössler A., Häfner H., Dütsch-Strobel A., et al. Further evidence for a specific role of estradiol in schizophrenia?. Biol Psychiatry 36 7 (1994) 492-494
82. Dong Y., and Benveniste E.N. Immune function of astrocytes. [review]. Glia 36 2 (2001) 180-190
83. Liu J., Shi Y., Tang J., et al. SNPs and haplotypes in the S100B gene reveal association with schizophrenia. Biochem Biophys Res Commun 328 1 (2005) 335-341
84. Rothermundt M., Ponath G., and Arolt V. S100B in schizophrenic psychosis. [review]. Int Rev Neurobiol 59 (2004) 445-470
85. Luk W.P., Zhang Y., White T.D., et al. Adenosine: a mediator of interleukin-1beta-induced hippocampal synaptic inhibition. J Neurosci 19 11 (1999) 4238-4244
86. Ho A., and Blum M. Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J Neurosci 18 15 (1998) 5614-5629
87. Kamata M., Higuchi H., Yoshimoto M., et al. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 10 2 (2000) 129-132
88. Shuto H., Kataoka Y., Horikawa T., et al. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res 747 2 (1997) 348-351
89. Bethus I., Stinus L., and Goodall G. Chronic interferon-alpha potentiates latent inhibition in rats. Behav Brain Res 144 1-2 (2003) 167-174
90. Lacosta S., Merali Z., and Anisman H. Central monoamine activity following acute and repeated systemic interleukin-2 administration. Neuroimmunomodulation 8 2 (2000) 83-90
91. McAllister C.G., van Kammen D.P., Rehn T.J., et al. Increases in CSF levels of interleukin-2 in schizophrenia: effects of recurrence of psychosis and medication status. Am J Psychiatry 152 9 (1995) 1291-1297
92. Nawa H., Takahashi M., and Patterson P.H. Cytokine and growth factor involvement in schizophrenia-support for the developmental model. Mol Psychiatry 5 6 (2000) 594-603
93. Zhang X.Y., Zhou D.F., Cao L.Y., et al. Changes in seruminterleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 65 7 (2004) 940-947
94. Müller N., Riedel M., Ackenheil M., et al. The role of immune function in schizophrenia: an overview. Eur Arch Psychiatry Clin Neurosci 249 Suppl 4 (1999) 62-68
95. Lin A., Kenis G., Bignotti S., et al. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 32 1 (1998) 9-15
96. Sperner-Unterweger B., Gaggl S., Fleischhacker W.W., et al. Effects of clozapine on hematopoiesis and the cytokine system. Biol Psychiatry 34 8 (1993) 536-543
97. Haack M., Hinze-Selch D., Fenzel T., et al. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis. J Psychiatr Res 33 5 (1999) 407-418
98. Boulanger L.M., and Shatz C.J. Immune signalling in neural development, synaptic plasticity and disease. Nat Rev Neurosci 5 7 (2004) 521-531
99. Wright P., Nimgaonkar V.L., Donaldson P.T., et al. Schizophrenia and HLA: a review. [review]. Schizophr Res 47 1 (2001) 1-12
100. Huh G.S., Boulanger L.M., Du H., et al. Functional requirement for class I MHC in CNS development and plasticity. Science 290 5499 (2000) 2155-2159
101. Dettling M., Schaub R.T., Mueller-Oerlinghausen B., et al. Further evidence of human leukocyte antigen-encoded susceptibility to clozapine-induced agranulocytosis independent of ancestry. Pharmacogenetics 11 2 (2001) 135-141
102. Vargas-Alarcón G., Yamamoto-Furusho J.K., Zuñiga J., et al. HLA-DR7 in association with chlorpromazine-induced lupus anticoagulant (LA). J Autoimmun 10 6 (1997) 579-583
103. Yazdani U., and Terman J.R. The semaphorins. Genome Biol 7 3 (2006) 211
104. Eastwood S.L., Law A.J., Everall I.P., et al. The axonal chemorepellant semaphorin 3A is increased in the cerebellum in schizophrenia and may contribute to its synaptic pathology. Mol Psychiatry 8 2 (2003) 148-155
105. Mah S., Nelson M.R., Delisi L.E., et al. Identification of the semaphorin receptor PLXNA2 as a candidate for susceptibility to schizophrenia. Mol Psychiatry 11 5 (2006) 471-478